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ABSTRACT
Continuous glucose monitoring (CGM) is a revolutionary addition to diabetic
management for patients with type 1 diabetes mellitus (T1DM). CGM, when used properly,
improves overall glycemic control. In the short term, CGM decreases incidences of
hypoglycemic events and improves day to day blood glucose control. In the long term, CGM
decreases hemoglobin A1c levels and decreases incidences and severity of long term
complications of diabetes. When patients are educated and supported by providers on the use of
CGM, patients with T1DM can achieve optimal glycemic control.
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Continuous Glucose Monitoring: An Overview for Nurse Practitioners
Introduction
The CDC National Diabetes Statistics Report (2017) states that over 1.5 million adults in
the United States are living with type 1 diabetes mellitus (T1DM). With an average of 40,000
individuals newly diagnosed with T1DM each year, it is predicted that over 5 million Americans
will be living with this chronic disease by the year 2050 (Centers for Disease Control and
Prevention, 2017). Although these statistics are concerning, it is even more disconcerting that
less than one-third of these individuals are adequately controlling their blood glucose levels to
achieve target goals (Pietrangelo, 2017). As a result of poor control and high prevalence, T1DM
costs the United States an average of $14.9 billion each year (Pietrangelo, 2017). Fortunately,
there is something that can help. The use of continuous glucose monitoring (CGM) has recently
become an important part of diabetic management and is helping to optimize the treatment of
T1DM in the United States and around the world (Slattery & Choudhary, 2017).
CGM is a system that constantly measures glucose levels in real time. A small catheter
containing a sensor is inserted under the skin and measures glucose levels in the subcutaneous
tissue fluid. The sensor connects to a transmitter that sends glucose data wirelessly to a handheld
monitoring device. Many models also have a mobile app available allowing users to see glucose
readings on their handheld electronic devices (Dexcom Continuous Glucose Monitoring, 2018).
Providers caring for patients with T1DM, and specifically nurse practitioners, can greatly
influence these patients’ lives by increasing their knowledge of the use of CGM in diabetes
management and how it can improve diabetes outcomes. CGM can be a life changing addition to
a patient’s diabetes management and should, therefore, be advocated by all healthcare providers
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(Pickup, Holloway, & Samsi, 2015). The purpose of this article is to give nurse practitioners an
overview of CGM and discuss the implications these systems can have for patients with T1DM.
History of Blood Glucose Monitoring
Blood glucose monitoring has improved greatly over the years. In the early 20th century,
people with T1DM had to test their urine to determine their blood glucose level and then selfadminister insulin according to the urine glucose reading (Clarke & Foster, 2012). This form of
testing was very inaccurate. The time delay involved in determining the glucose by testing urine
and the long-acting nature of the insulin made it nearly impossible to titrate insulin for tight
glycemic control (Clarke & Foster, 2012). It was not until 1980 that home self-monitoring blood
glucose (SMBG) was introduced. SMBG allows people with T1DM to test a drop of blood from
a fingerstick and determine their blood glucose level at that specific point in time (Clarke &
Foster, 2012). This form of testing is much more accurate than urine dips, but only allows for
tight glycemic control when the blood is tested very regularly throughout the day. The
emergence of CGM fills the gaps between finger sticks by relaying a continuous blood glucose
trend. With increased knowledge of their current blood glucose status, patients are better able to
treat their diabetes (El-Laboudi, Godsland, Johnston, & Oliver, 2016).
CGM was created to help patients with T1DM to further improve their blood glucose
control. Blood glucose levels are ever changing, and CGM offers a continuum of these
constantly trending values. Monitoring blood glucose with SMBG finger sticks provides only a
single value on this continuum making it difficult for patients to treat their blood glucose
proactively. In contrast, CGM not only provides a real-time blood glucose level, but also shows
trends, direction, and speed of change. Glucose levels are updated as frequently as every five
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minutes. The additional information of glucose trends allows users to treat their diabetes with
precision and ultimately achieve better glycemic control (Medtronic MiniMed Inc., 2018).
Importance of CGM as a Treatment Option
Evidence shows that using CGM has both short- and long-term benefits for patients with
T1DM (Floyd et al., 2012). In the short term, CGM improves day to day blood glucose control
and prevents the occurrence of hypoglycemic events (Slattery & Choudhary, 2017). CGM
systems are programmed to identify a downward trend in blood glucose levels and will alarm if
levels drop below a programmed set point that each user can designate. CGM has also been
shown to decrease hemoglobin A1c (HbA1c) levels and, therefore, decrease the long-term
consequences of poor glycemic control (Lind et al., 2017). In a monumental study done in 1993
by The Diabetes Control and Complications Trial Research Group, tight glycemic control was
effective at reducing kidney damage by 54%, cardiovascular damage by 41%, eye damage by up
to 53%, and nerve damage by up to 41% (Shamoon et al., 1993). In addition to improving
glycemic control, CGM has also been shown to decrease glucose fluctuations, reducing
endothelial oxidative stress that ultimately reduces long-term complications of diabetes,
especially those of a cardiovascular nature (Tumminia et al., 2015). By reducing glucose
fluctuations and tightening glycemic control, CGM can reduce the incidence of long-term
complications for patients with T1DM.
Many patients with T1DM use an insulin pump to deliver their insulin continuously
through a subcutaneous catheter. Adding a CGM system to this regimen in conjunction with an
insulin pump proves to be even more beneficial in the long-term than simply a CGM on its own
(Mauras, Fox, Englert, & Beck, 2013). Patients with both devices can read their CGM meter and
immediately adjust insulin delivery accordingly as the devices sit side by side. With the newest
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CGM models, which are hybrid systems combining CGM with an insulin pump, glucose data
and insulin delivery data can be viewed simultaneously on any smart device. In this manner,
CGM use has been attributed to more frequent self-adjustments of insulin, which contributes to
an overall improvement in glycemic control (Battelino et al., 2012).
Research also shows that long term use of CGM not only offers better glycemic control,
but also increased patient satisfaction for patients with T1DM. The patients report an overall
improvement in their quality of life when using the CGM system (Slattery & Choudhary, 2017).
This satisfaction and improved outcomes may be attributed to the fact that patients with T1DM
report that using a CGM system simplifies diabetic management and assists in recognizing
hypoglycemia (Patton & Clements, 2016). Decreasing the fear of hypoglycemia and simplifying
daily living for these patients has been shown to significantly increase the quality of life of CGM
users (Chamberlain, Dopita, Gilgen, & Neuman, 2016).
An additional benefit is one of long-term economic consequence. In a study by Bronstone
and Graham in 2016, a cost calculation demonstrated the estimated cost savings of CGM use: in
a T1DM population of 9300, routine use of CGM would yield an annual savings of $946-$1346
per patient (Bronstone & Graham, 2016). This cost savings is primarily related to a decrease in
hospitalizations and emergency treatment events related to hypoglycemic complications
(Chamberlain et al., 2016).
Evidence of CGM Efficacy
Extensive research has been done on the efficacy of CGM. The results clearly indicate
that CGM improves glycemic control when used appropriately. All of the research done in
regards to the efficacy of CGM has concluded that it allows patients with T1DM to improve their
glycemic control.
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CGM provides two main outcomes for patients with T1DM: reduction of HbA1c levels
and reduction of time spent in hypoglycemia (Mauras et al., 2013). A systematic review done in
2012 found that on average a reduction of 0.7% in HbA1c was seen at 3-18 months after CGM
initiation (Langendam, Luijf, Hooft, DeVries, Muddle, & Scholten, 2012). Another study
reported an average reduction of 0.5-0.7% in HbA1c levels over 9 months when using CGM
(Parkin, Graham, & Smolskis, 2017). These levels are even further reduced for patients who use
CGM consistently and proactively (Floyd et al., 2012). Another recent study found a mean
reduction in HbA1c of 1.0% after 24 weeks of wearing the CGM system an average of 6 days
per week (Beck et al., 2017). Additional researchers found that patients with poorly controlled
T1DM taking multiple daily injections of insulin had a decrease in HbA1c from 8.35% to 7.92%
over 26 weeks with the use of CGM. This shows that even those with poor control can benefit
from CGM (Lind et al., 2017). A study done in an adolescent population (ages 11-20 years), with
poor glycemic control, found that even while only wearing the CGM monitor an average of
4.262 days a week, there was an average reduction of 1.1% in HbA1c levels (Lewis, McCrone,
Deiriggi, & Bendre, 2017). In addition to reducing HbA1c levels, CGM has also been shown to
reduce the incidence of hypoglycemia. In particular, the use of CGM can nearly eliminate the
occurrence of severe hypoglycemia- a blood sugar level low enough to impair daily activities
(Choudhary et al., 2013).
The average reduction seen throughout the research is around 0.7%, which is equivalent
to decreasing the average blood sugar by 20mg/dL. For example, a patient with a HbA1c of 8.6%
has an average blood glucose of 200mg/dL, while a patient with a HbA1c of 7.9% has an
average blood glucose of 180mg/dL. Even a 1.0% decrease in HbA1c reduces the risk of death
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related to diabetes complications by 21% and has also been shown to reduce microvascular
complications by 37% and risk of heart attack by 14% (Stratton et al., 2000).
Another benefit of CGM is the use of nocturnal data to treat glucose trends. Prior to
CGM, the only data available to analyze glucose trends were the SMBG levels provided by the
patient and the HbAlc blood level tested by the provider. SMBG and HbAlc alone cannot
provide a picture of hypoglycemia duration or nocturnal hypoglycemia, as patients do not
typically test their blood while sleeping (Kusunoki et al., 2015). With CGM, data are provided
about glucose trends during sleep and can, therefore, be used by a provider to adjust insulin
delivery accordingly. These data are particularly useful in conjunction with insulin pump therapy
as the basal rate delivery of insulin can be adjusted to fit the individual glucose patterns of the
patient. The use of nocturnal data ultimately increases the amount of time the patients spend
within their target blood glucose range (Sharifi et al., 2016).
Identifying Candidates for CGM
Ideally, all patients with T1DM would be candidates for CGM; however, this is not the
case. Socioeconomic factors are paramount in identifying potential candidates for a CGM
system. One study indicated that low-income patients with minimal diabetes education do not
achieve any improvement in HbAlc levels when using CGM (Sequeira, Montoya, Ruelas, Xing,
Chen, Beck, & Peters, 2013). Although unable to achieve improvement in glycemic control, the
subjects in this study did indicate that the CGM made it easier for them to adjust their insulin
dosing and the majority wanted to continue with CGM (Sequeira et al., 2013).
Unfortunately, insurance companies’ reimbursement policies dictate how patients receive
healthcare. Each insurance company has its own set of qualifications for CGM coverage.
Without insurance, a CGM system is unaffordable for many patients, and some insurance
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companies may not provide adequate coverage to make using the CGM system an economical
option. Historically, insurance companies have generally provided just minimal coverage for
CGM. Medicare, for example, has not until recently covered the cost of CGM systems, but in
2017 Medicare announced it will cover the Dexcom G5 CGM system (Shifflett, 2018). This
announcement will open the opportunity for CGM to many patients with T1DM. Another
economic barrier is the need for continued supplies, which can also be costly with or without
insurance coverage (Shifflett, 2018). The CGM meter, insertion sites, transmitter, and site
adhesives must be purchased by the patient on a regular basis. Candidates for a CGM system
must have the means to replenish these supplies consistently in order to achieve the maximum
benefit of CGM. A CGM meter itself can cost anywhere from $200 - $1000, not including the
supplies needed to run the CGM system which can cost an average of $75 - $150 a month
(Scheiner, 2018). All of these costs are out of pocket for the patient after insurance. A patient
without insurance, paying cash for the meter and supplies, can expect to pay even more. For
example, the Dexcom G6, one of the newest CGM models, has a retail cost of $365 for the
receiver, $475 for a bundle of two transmitters, and $349 for a monthly supply of sensors
(Hoskins, 2018). In comparison, a SMBG kit can be purchased over-the-counter for an average
of $20, without insurance, and free for patients with insurance coverage. The testing strips for a
SMBG kit are even more economical at around 25 cents each with insurance coverage and $2
each without insurance. Nurse practitioners can assist patients with T1DM progress towards
qualifying for a CGM by being informed about the different insurance companies’ parameters
and helping patients to understand these qualifications.
Several other factors are also important in considering potential candidates for CGM.
Research has shown that CGM systems work best in highly motivated patients of all ages. With
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appropriate support, these patients can proactively calibrate their meter, use their meter
consistently, and take action according to glucose trends (Mauras et al., 2013). Research has also
shown that patients who participate in frequent and high intensity exercise can benefit from
CGM as its accuracy and effectiveness is not altered my metabolic changes (Bally, Zueger, Pasi,
Carlos, Paganini, & Stettler, 2016).
An additional consideration is the predicted compliance of the patient. High levels of
compliance and frequent interaction with the CGM system is essential to reaping the benefits.
Patients with low compliance and low motivation do not appear to benefit significantly from a
CGM system (Slattery & Choudhary, 2017). However, several studies have indicated that even
patients with poorly controlled diabetes benefit from CGM use as even minimal use of CGM
results in a lower HbA1c level (Lewis et al., 2017). Poorly controlled diabetes, therefore, does
not rule out a patient from CGM benefits (Lind et al., 2017).
Potential Barriers to CGM Use
Even among ideal candidates, there are still several barriers to appropriate CGM use. The
meter must be plugged in once daily to recharge, making CGM an impractical option for
homeless or transient populations. Also, one study concluded that CGM use was most
appropriate and effective in patients with higher education, higher household income, private
health insurance, longer duration of diabetes, and concurrent use of an insulin pump (Wong et
al., 2014).
An additional challenge with CGM is wearing the transmitter and the complexity of the
system. The insertion site can be uncomfortable and requires frequent changing. Patients also
complain of the nuisance of wearing two separate insertions sites, one for their insulin pump and
one for their CGM sensor, as CGM is most frequently used in conjunction with insulin pump
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therapy (Giani, Snelgrove, Volkening, & Laffel, 2017). With the two insertion sites also comes
the added burden of carrying two devices: a pump and a CGM receiver (Giani et al., 2017). For
example, patients with T1DM must keep track of the two devices at all times and adjust their
wardrobe so that they have pocket space to keep these devices on their person at all times as
well. The hassle of having another inserted device and negative associations with the device
being on the body are additional common barriers seen particularly in young adults (Tanenbaum,
Adams, Hanes, Barley, Miller, Mulvaney, & Hood, 2017). Some patients also report increased
anxiety with using a CGM system related to the complexity of the system, frequent alarms, and
sleep disturbances (Patton & Clements, 2016).
Types of CGM
There are three major companies that currently supply CGM systems: Dexcom, Abbott,
and Medtronic. Dexcom was the first to come out with CGM and they have continued to release
new and improved models since they went public in 2005 (Dexcom Continuous Glucose
Monitoring, 2018). Their most recent model is the Dexcom G6. Abbott’s CGM system, the
FreeStyle Libre, became available in the United States in December of 2017. While superbly
accurate, the Libre only displays glucose data when the transmitter is scanned across the sensor,
and does not transmit data continuously like the other models (FreeStyle Libre Inc., 2018).
Medtronic offers a CGM system called Guardian Connect that has previously only been
available as an integrated piece of their most recent insulin pump models- the MiniMed 630G
and MiniMed 670G (Medtronic MiniMed Inc., 2018). In March 2018, the Guardian Connect
system became available to the public for use as a CGM only, not linked to a pump, and is
geared towards use in patients on multiple daily injections (Medtronic MiniMed Inc., 2018).
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Research has been done comparing the Abbott and Dexcom systems, but none has been
done yet concerning the Guardian Connect CGM system on its own. The FreeStyle Libre and
Dexcom G4 Platinum have comparable accuracy and agreement with true blood glucose values
(Bonora, Maran, Ciciliot, Avogaro, & Fadini, 2016). However, another study found that the
Libre had greater precision in hypoglycemia, hyperglycemia, and during exercise (Aberer et al.,
2017). Each of the CGM systems has its pros and cons which should be considered and catered
to each individual patient.
Table 1
Comparison of CGM systems
Dexcom
Calibration by
Not needed, but can
fingerstick
be done if desired
Cost per year with
insurance
Covered by Medicaid
Life of sensor
Life of transmitter

≈ $4700

Abbott
No, not able to
receive calibrations.
Factory calibrated
prior to purchase.
≈ $730

Yes for the G5 model
Approved for 10 days
3-month battery life

Yes
Approved for 14 days
Approved for 10 days

Display options

App on smart device,
Tandem pump, or
handheld receiver
2 hrs.
Age 2 years and up

Handheld receiver,
must be touched to
sensor to receive data
12 hrs.
Age 18 years and
older

Warm up time
FDA approval

Medtronic
Yes, demands
calibration 3-4x/day

No
Approved for 7 days
7 days and then must
be removed and
recharged
App on smart device
or Medtronic pump

≈ $5200

2 hrs.
Age 14-75 years

*Information gathered from FreeStyle Libre, Inc., Dexcom Continuous Glucose Monitoring,
Medtronic MiniMed Inc., and Scheiner (2018)
Evolution of CGM
CGM has evolved significantly in the last decade. Since the first CGM system was
available to the public in 2005, the performance of these systems has only improved in
consistency and accuracy (Dubois, 2010). In 2016, a new device was released by Medtronic that
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is a combination CGM device and insulin pump (Medtronic MiniMed Inc., 2018). This device,
called the MiniMed 670G, is a hybrid closed loop system and the first of its kind in that it
automatically takes action for the patient in adjusting insulin delivery according to the CGM
values. For instance, if glucose levels go above or below designated values, the device will
increase or decrease the basal rate of insulin delivery to treat the glucose trend (Rossetti et al.,
2017). This new technology is monumental for people with T1DM and holds great promise for
the future of diabetic care. As technology continues to improve, it is likely that CGM will
become part of mainstream treatment for patients with T1DM. This will ultimately eliminate the
need for painful finger sticks and improve glycemic control in the short- and long-term
(Forlenza, Argento, & Laffel, 2017).
Monitoring and Evaluating Effectiveness of CGM Therapy
Data from a CGM system reach optimal effectiveness when it is accessed and analyzed.
Data can be downloaded to a computer directly from the meter and glucose trends evaluated in
order to make changes to the patient’s practices. Each type of CGM system has its own program
or website with a method of displaying the glucose values (Scheiner, 2018). Graphs of trends are
especially useful in discussing necessary changes with patients. When patients can see their own
glucose data in graphical form, their understanding and motivation for change increases.
Quarterly visits are recommended for ideal diabetes management. At these visits,
providers can encourage patients with T1DM to wear their meter more often, ideally all the time.
Although benefits from the system are seen with only 40% compliance, the benefits increase
with increased compliance (Tumminia et al., 2015). Providers can also address barriers to CGM
system use and discuss ideas for improving compliance with the system (Pickup et al., 2015).
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Providers should also take time during these visits to educate how CGM use is linked to
improved HbA1c levels and overall improved glycemic control (Tanenbaum et al., 2017).
Patient Teaching
Several points of education should be addressed with patients about their CGM system. It
is important to educate patients that although undoubtedly helpful, CGM does not replace their
need to critically think (Giani et al., 2017). Technology is not always perfect, and, therefore,
patients must trust how they feel and test their blood if they feel their blood glucose level is
different from what the meter is reporting. Each CGM system also comes with a manual that can
assist the patient in troubleshooting the meter if it reports an error or is malfunctioning (Shifflett,
2018). Patients should be directed towards these manuals and individual education provided as
needed. In a qualitative study conducted to analyze the experiences of patients with CGM, it was
found that a lack of knowledge about CGM was a common theme among general practitioners.
Healthcare providers must educate themselves on CGM in order to enhance the efficacy of its
use for patients with T1DM (Pickup et al., 2015).
Conclusion
CGM improves overall glycemic control in both the short and long term and also
decreases incidence and severity of diabetes related complications for patients with T1DM.
CGM is most beneficial when properly used by motivated patients of all ages. When a healthcare
provider appropriately educates and supports patients and patients comply with the established
plan of care, optimal glycemic control can be achieved for patients with T1DM using CGM.
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